Treatment With Probiotics (Saccharomyces Boulardii) and Its Role in Bacterial Translocation and Immune Reconstitution in VIH Infection.
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 44
- 试验地点
- 2
- 主要终点
- To evaluate microbial translocation-Binding lipopolysaccharide Protein (LBP).
研究概览
简要总结
Objectives: MAIN: To evaluate the parameters of microbial translocation after treatment with probiotics (Saccharomyces boulardii) in HIV+ patients and its role on immune reconstitution and the changes in gut microbiota composition.
SECONDARY OBJECTIVES: 1) To analyze the progress of immune activity markers after the administration of probiotics. 2) To determine the improvement of CD4+ lymphocytes and HIV viral load in patients after taking probiotics.
Methods: Design: A prospective randomized open controlled double-blinded trial, to be performed at a tertiary care hospital in Barcelona. Subjects: Chronic HIV infected patients. Sample size: 44 cases. They´ll be divided in 2 groups: (1) Patients with CD4 +> 400 cells / ml and undetectable viral load for more than two years (22 cases) and (2) Patients with immunodiscordancy, defined as patients with CD4 + T cells lower than 350 cells / ml despite 4-7 years of effective antiretroviral therapy. (22 cases). Intervention: Patients were randomized in 2 subgroups: (A) they´ll receive daily oral supplementation with S. boulardii for 3 months and (B) they ´ll receive placebo. Variables: bacterial lipopolisaccharide levels measured by the Lipid-Binding protein (LBP), parameters of immune activation in plasma (soluble CD14, IFN-Υ, TNF-Alpha, IL (interleukine)-2, IL-5, IL-6, IL-12)and gut microbiota composition prior to the use of probiotics (baseline), at 3 and 6 months. Immunological and clinical data. Outcome measures: quantification of bacterial translocation levels, markers of activity and immune recovery. Analysis: Comparison of variables before and after the intervention. The analysis will be performed by biological and immunological effectiveness.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with chronic HIV infection and viral load undetectable > two years with stable ART CD4> 400 cells / ml.
- •Patients with chronic HIV infection and viral load undetectable> two years with stable ART CD4 <350 cells / ml.
- •Inform consent signed.
- •Aged between 18- No limit.
排除标准
- •Patients who receive or have received in the past 6 months food supplements containing probiotics.
- •Patients who have received antibiotic treatment in the last two months
- •Patients who are poor presupposes adherence to dietary supplements.
- •Patients who have changed the TAR in the last three months.
结局指标
主要结局
To evaluate microbial translocation-Binding lipopolysaccharide Protein (LBP).
时间窗: From randomisation to 6 months.
To evaluate Gut microbiota composition.
时间窗: From randomisation to 6 months.
Change in gut microbiota (454 pyrosequencing of fecal samples).
次要结局
- To evaluate Markers of immune activity: soluble CD14 (sCD14), interferon gamma (IFN-Υ), tumor necrosis factor (TNF), IL-6, Reactive C protein, D -dimer, fibrinogen.(From randomisation to 6 months.)
- Analyse parameters that determine the immune status: CD4 + lymphocyte count, CD 8 + and HIV viral load.(From randomisation to 6 months.)
研究者
JVillar
MD
Parc de Salut Mar
